Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne, Turkey.
Trakya University School of Medicine, Edirne, Turkey.
J Gastrointest Cancer. 2022 Mar;53(1):31-40. doi: 10.1007/s12029-021-00675-1. Epub 2021 Jul 24.
Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure.
We evaluated local and locally advanced TCC patients between 2007 and 2020 years for demographics data, symptoms, treatment status, and histopathological and molecular features.
Overall, 107 TCC patients were included in this study. According to the molecular data analysis of 44, 35, and 23 patients for MSI, RAS, and BRAF status, respectively, 7 (15.9%) were MSI-H, 13 (37.1%) were RAS mutant, and 11 (47.8%) had BRAF V600E mutation. The median follow-up time was 31.5 months. Median disease-free survival (DFS) was 5.19 months, and median OS was 88.3 months for the whole study population. The tumor stage was the most significant prognostic factor for DFS and OS. Although BRAF mutation was not a significant marker for DFS, it was an independent prognostic marker for OS (HR 3.90 95% CI 1.42-10.7). There were no statistically significant differences between proximal two-thirds and distal one-third tumor location.
TCC has molecular features and prognostic factors more likely RCC and no differences between proximal and distal sub-parts. BRAF V600E mutation status is an independent predictor of survival even in the early stages of TCC.
横结肠癌（TCC）是一种罕见的疾病，占所有结肠癌的 10%。TCC 更倾向于右半结肠癌。我们旨在研究 TCC 是否通过使用在结肠癌中已知重要的临床、病理和分子预后因素来区分于其他结肠癌肿瘤，以及它是否在其自身的解剖结构上有所不同。
我们评估了 2007 年至 2020 年期间局部和局部晚期 TCC 患者的人口统计学数据、症状、治疗状况以及组织病理学和分子特征。
总体而言，本研究纳入了 107 例 TCC 患者。根据对 44、35 和 23 例患者的 MSI、RAS 和 BRAF 状态的分子数据分析，分别有 7 例（15.9%）为 MSI-H，13 例（37.1%）为 RAS 突变，11 例（47.8%）有 BRAF V600E 突变。中位随访时间为 31.5 个月。全组无复发生存（DFS）为 5.19 个月，总生存（OS）为 88.3 个月。肿瘤分期是 DFS 和 OS 的最重要预后因素。虽然 BRAF 突变不是 DFS 的显著标志物，但它是 OS 的独立预后标志物（HR 3.90，95%CI 1.42-10.7）。近端三分之二和远端三分之一肿瘤位置之间无统计学显著差异。
TCC 具有分子特征和预后因素，更类似于 RCC，且近端和远端亚部位之间无差异。BRAF V600E 突变状态是 TCC 早期生存的独立预测因子。
